Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
HOME > COMMENTARY
COMMENTARY
-
Gene Therapies Expand into AMD, Raising Promise and Cost Concerns
April 24, 2026
-
Challenges in a Post-AG Era: Ensuring a Reliable Supply System
April 6, 2026
-
Japan’s FY2026 R&D Tax Credit Reform Wins Broad Industry Backing
April 1, 2026
-
A “Core Industry” in Name Only? Drug Pricing Reform Leaves a Sour Taste
March 24, 2026
-
Beyond Elevidys: Next-Generation DMD Therapies Advance through Multiple Approaches
March 11, 2026
-
Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause
March 10, 2026
-
ICH Weighs Need for Biosimilar Efficacy Trials as Regulators Move Away from Routine Use
March 9, 2026
-
G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands
February 25, 2026
-
Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?
February 18, 2026
-
Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision
February 9, 2026
-
Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
February 5, 2026
-
TSE’s Growth Market Reform Puts Pressure on Biotechs
January 27, 2026
-
Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026
January 6, 2026
-
Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise
December 22, 2025
-
FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed
December 9, 2025
-
MOF Autumn Proposals Signal a Shift from Drug Pricing to Cost-Sharing Reform
November 17, 2025
-
Japan’s Trading Houses Gain Ground in Pharma, Rewriting the Industry Playbook
November 10, 2025
-
The Price of Stability: Who Bears Japan’s Drug Distribution Burden?
October 27, 2025
-
Inside Eylea - 2: Will a Bio-AG Return after Six Years? Pricing Debate Resumes
October 7, 2025
-
Inside Eylea - 1: Patent Issues Behind Differences in Biosimilar Indications for AMD and DME
October 6, 2025
